Health
Parvovirus or ‘slapped cheek disease’ is on the rise, CDC warns: Here’s what to know
A respiratory disease known as parvovirus B19 is on the rise in the U.S. among all age groups, according to a recent advisory from the U.S. Centers for Disease Control and Prevention (CDC).
The CDC issued the health alert on Aug. 13 after European public health authorities reported “unusually” high numbers of cases in 14 countries during the first quarter of 2024, the advisory said.
The virus typically causes a blotchy rash on the cheeks that appears as if someone has slapped them — hence its nickname, “slapped cheek disease.”
WITH MPOX A PUBLIC HEALTH EMERGENCY IN AFRICA, WHAT YOU MUST KNOW ABOUT INCREASED VIRUS RISK
“Parvovirus can be a very mild infection in many people, but if you are pregnant or are immunocompromised in any way, you are at a much greater risk of serious illness,” Dr. Aaron Glatt, chief of infectious diseases at Mount Sinai South Nassau Hospital on Long Island, New York, told Fox News Digital.
What is parvovirus B19?
Parvovirus B19 is a virus that can be easily spread by respiratory droplets in the air after an infected person coughs or sneezes, according to the CDC.
A respiratory disease known as parvovirus B19 is on the rise in the U.S. among all age groups, according to a recent advisory from the U.S. Centers for Disease Control and Prevention (CDC). (iStock)
Children are often infected at school and spread it to other kids through close personal contact, then later to adults when they come home, experts say.
Approximately 50% of people who were not previously infected contract the virus from an infected family member — while 20% to 50% of susceptible students and staff become infected during school outbreaks, the advisory notes.
“The virus is highly contagious and can spread asymptomatically,” Dr. Marc Siegel, senior medical analyst for Fox News and clinical professor of medicine at NYU Langone Medical Center, told Fox News Digital.
WEST NILE DEATH REPORTED IN TEXAS AS HEALTH OFFICIALS WARN RESIDENTS TO SAFEGUARD AGAINST MOSQUITOES
Parvovirus B12 is also known as “fifth disease” because it was previously listed fifth on a list of common childhood viral illnesses that cause rashes, according to Mayo Clinic.
(The top three on this list are measles, rubella and scarlet fever.)
Symptoms of the virus
Many people who get infected don’t have symptoms, but some will experience sickness, according to the advisory.
About a week after an exposure, susceptible children may complain of flu-like symptoms, including fever, muscle pain and fatigue, which generally last less than a week.
People are most contagious in this early phase of the illness.
The virus typically causes a blotchy rash on the cheeks that appears as if someone has slapped them — hence the nickname “slapped cheek disease.” (iStock)
Several days after the fever starts, children often develop the hallmark blotchy “slapped cheek” rash — a helpful clue that health care providers use to diagnose the illness.
People are generally not infectious by the time they develop the rash, experts say.
A fine, “lacy” rash may follow on the chest, back, buttocks, or arms and legs that is sometimes itchy, according to the CDC. It usually goes away in about a week to 10 days.
WEST NILE DEATH REPORTED IN TEXAS AS HEALTH OFFICIALS WARN RESIDENTS TO SAFEGUARD AGAINST MOSQUITOES
Adults are less likely to develop the “slapped cheek” rash. Their most common symptoms are a generalized rash on the body and joint pain that affects the hands, feet and knees.
In some cases, adults only experience joint pain, which usually lasts one to three weeks – although it can last for months. It usually resolves without long-term complications.
Antibodies provide immunity
Antibodies from prior infection help prevent recurrence of parvovirus B12, the CDC said.
“Once infected, you have a lifetime immunity,” Siegel noted.
The largest increase in infections was among children ages 5 to 9.
Most adults in the United States are immune — with 50% having detectable antibody levels by age 20, and more than 70% acquiring them by age 40, per the advisory.
LISTERIA INFECTION LINKED TO DELI MEATS KILLS 2, INFECTS 28 ACROSS US, CDC WARNS
The share of people who have had a recent infection dropped below 3% between 2022 and 2024, but increased to 10% in June of this year.
The largest increase in infections was among children ages 5 to 9, going from 15% to 40% in that time frame, the health alert noted.
People who work in settings with close contact with children, such as schools and day cares, are at a greater risk of infection.
High-risk populations
Most healthy adults and children only have a mild illness, but people with weakened immune systems, pregnant women and those with chronic blood disorders can develop serious health complications from this virus, according to the CDC.
“Anyone with those conditions should be very quick to seek out medical attention to help address potential complications,” Glatt noted.
Pregnant women who are susceptible to the virus may spread the illness to their babies, the CDC warned. (iStock)
Pregnant women who are susceptible to the virus may spread the illness to their babies, the CDC warned.
“Unfortunately, there is an increased risk of miscarriage if you get parvovirus during pregnancy,” Glatt said.
Parvovirus infection may lead to adverse outcomes — such as severe anemia in the fetus and miscarriage — in 5% to 10% of cases during pregnancy, with the highest risk at between 9 and 20 weeks of fetal gestation, per the advisory.
While parvovirus B19 can affect humans of all ages, only two out of 10 individuals will have physical symptoms. (iStock)
“There is an increased risk of complications in patients with significant immunocompromising conditions, such as those who have leukemia, have received an organ transplant or have an HIV infection,” Glatt added.
Since most adults are immune to the virus, however, many pregnant women are protected from the virus, the CDC noted.
Treatment is mainly ‘supportive care’
Infected pregnant women primarily receive supportive care, which means treating the underlying symptoms and monitoring for severe fetal anemia, according to the advisory.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
People with weakened immune systems or those with chronic blood disorders can sometimes develop bone marrow failure as a result of the virus, the advisory added.
In that case, treatment often includes blood cell transfusions and intravenous immunoglobulin (IVIG).
People are generally not infectious by the time they develop the rash, experts say. (iStock)
(IVIG is a collection of antibodies that strengthens the immune system, according to Mayo Clinic’s website.)
There is currently no vaccine to prevent parvovirus B19, and most people infected with the virus will recover without any long-term complications.
For more Health articles, visit www.foxnews.com/health
“While there is no specific treatment for parvovirus infection, recognizing the complications and addressing them early may be of benefit,” Glatt added.
Hand-washing can also help to prevent transmission, according to Siegel.
Health
4 Mistakes People Make When Starting a GLP-1 That Can Stall Weight Loss—Plus How to Maximize Your Results
Use left and right arrow keys to navigate between menu items.
Use escape to exit the menu.
Sign Up
Create a free account to access exclusive content, play games, solve puzzles, test your pop-culture knowledge and receive special offers.
Already have an account? Login
NEWYou can now listen to Fox News articles!
With an aggressive new strain spreading across the country, this year’s flu season has been marked by record-high hospitalizations and reportedly intense symptoms.
As people look for ways to contain the spread, new research has found that a few simple factors can greatly reduce transmission.
Researchers from the University of Maryland Schools of Public Health and Engineering in College Park and the School of Medicine in Baltimore studied influenza spread by placing flu-positive college students in a hotel room with healthy middle-aged adult volunteers.
FLU HOSPITALIZATIONS HIT ALL-TIME WEEKLY HIGH IN DENSELY POPULATED STATE, OFFICIALS WARN
The study, published in the journal PLOS Pathogens, is reportedly the first clinical trial investigating how the flu spreads from naturally infected people to uninfected people, according to a press release.
The participants, including 11 healthy volunteers, lived on a quarantined floor of a Baltimore-area hotel for two weeks. During that time, they simulated interactions, including having conversations, doing physical activities like yoga, and passing around objects like pens and tablets from infected people to the rest of the group.
New research has experts questioning how the flu spreads through airborne transmission. (iStock)
Researchers monitored the participant’s symptoms, performed daily nasal swabs, and collected saliva and blood samples to test for antibodies, the release stated.
The study also measured the “viral exposure” in the volunteers’ breathing air and ambient air in the activity room. The exhaled breath of the participants was measured by a machine called the Gesundheit II, invented by researcher Dr. Donald Milton and colleagues at Harvard T.H. Chan School of Public Health.
COULD DENTAL FLOSS BE THE NEXT VACCINE METHOD? SCIENTISTS SAY IT COULD WORK
At the end of the experiment, none of the healthy individuals had become infected with the flu due to a variety of factors. This included a lack of coughing, as the infected students were holding “a lot of virus in their noses” and only small amounts were “expelled into the air,” the researchers noted.
Researchers said proper ventilation was a major factor in halting flu spread in this study. (iStock)
“Our data suggests key things that increase the likelihood of flu transmission — coughing is a major one,” Dr. Jianyu Lai, post-doctoral research scientist and the study’s lead data analyst and report writer, shared in a statement.
CLICK HERE FOR MORE HEALTH STORIES
The other factor was ventilation and air movement, as the air in the study room was “continually mixed rapidly by a heater and dehumidifier, and so the small amounts of virus in the air were diluted,” Lai pointed out.
The researcher added that middle-aged adults are “usually less susceptible” to influenza than younger adults.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
Most researchers assume that airborne transmission is a major factor of disease spread, according to Dr. Donald Milton, professor at SPH’s Department of Global, Environmental and Occupational Health and a global infectious disease aerobiology expert.
“At this time of year, it seems like everyone is catching the flu virus, and yet our study showed no transmission,” he said in the same press release. “What does this say about how flu spreads and how to stop outbreaks?”
There have been 81,000 flu-related hospitalizations and more than 3,000 deaths in the U.S. this year so far, data shows. (iStock)
Milton, who was reportedly among the first experts to identify how to stop the spread of COVID-19, noted that findings from these types of trials are essential to updating international infection-control guidelines.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
“Being up close, face-to-face with other people indoors where the air isn’t moving much, seems to be the most risky thing — and it’s something we all tend to do a lot,” he said.
“At this time of year, it seems like everyone is catching the flu virus, and yet our study showed no transmission.”
“Our results suggest that portable air purifiers that stir up the air, as well as clean it, could be a big help,” Milton suggested. “But if you are really close and someone is coughing, the best way to stay safe is to wear a mask, especially the N95.”
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
Approximately 11 million flu illnesses and about 5,000 deaths have occurred so far in the 2025-2026 influenza season, according to CDC data. A large share of the current flu cases are caused by the new influenza A subclade K variant.
NEWYou can now listen to Fox News articles!
GLP-1 has become a popular buzzword in the weight-loss community — but now some are touting “GLP-3s,” claiming they are taking obesity medications to the next level.
GLP-1 (glucagon-like peptide-1) medications work by mimicking a naturally occurring hormone in the body that helps regulate blood sugar and appetite.
The informal term “GLP-3” refers to a new triple-agonist drug that targets three hormones: GLP-1, GIP (glucose-dependent insulinotropic polypeptide, another naturally occurring hormone released by the gut after eating) and glucagon receptors. The most advanced example is retatrutide by Eli Lilly, according to clinical trial outcomes.
OBESITY EXPERT REVEALS THE BEST WAY TO DECIDE IF GLP-1S ARE RIGHT FOR YOU
The New England Journal of Medicine published results from a 2023 phase 2 retatrutide trial for obesity, revealing “substantial reductions in body weight” after 48 weeks of treatment.
A 12 mg once-weekly injection led to a 24.2% weight reduction, and participants continued to drop pounds after the 48-week trial period.
GLP-1 (glucagon-like peptide-1) medications work by mimicking a naturally occurring hormone in the body that helps regulate blood sugar and appetite. (iStock)
Side effects were reportedly similar to GLP-1 medications, most commonly including gastrointestinal complications like nausea, vomiting and diarrhea. Heart rate increases were noted, depending on the dose.
How it’s different
Retatrutide mimics three natural hormones found in the body, compared to GLP-1s that simulate just one hormone, according to a report by GoodRx pharmacists.
GIP and GLP-1 hormones signal the pancreas to release insulin after eating, while slowing digestion to help initiate feelings of fullness.
NEW WEGOVY PILL OFFERS NEEDLE-FREE WEIGHT LOSS — BUT MAY NOT WORK FOR EVERYONE
These hormones target the area of the brain that regulates appetite and influences food cravings, the report noted.
The third hormone, glucagon, speeds up metabolism and helps the body break down fat cells for energy. That hormone also tells the liver to make new sugar, which is kept in check by GIP and GLP-1 activity, preventing blood sugar spikes.
Participants in the phase 3 trial saw an average weight loss of 71.8 pounds. (iStock)
“This added metabolism boost can add to and complement GIP’s and GLP-1’s actions. And that’s why it seems to provide significant weight loss,” the GoodRx website states. “If approved, retatrutide will be the first in a new class of medications.”
Eli Lilly announced results from its phase 3 trial TRIUMPH-4 in December, testing retatrutide’s effect on weight loss and other health conditions.
“We believe retatrutide could become an important option for patients with significant weight loss needs and certain complications.”
Participants with obesity and knee arthritis who took a 12-mg dose of retatrutide saw an average weight loss of 71.8 lbs (28.7%) at 68 weeks.
“For retatrutide, the findings from TRIUMPH-4 are encouraging, and with seven additional phase 3 readouts expected in 2026, we believe retatrutide could become an important option for patients with significant weight loss needs and certain complications, including knee osteoarthritis,” a Lilly spokesperson said in a statement to Fox News Digital.
CLICK HERE FOR MORE HEALTH STORIES
The drug also reduced Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain scores by an average of 75.8%, marking “significant improvements” in comfort level and physical function.
More than one in eight patients reported being “completely free” from knee pain at the end of the trial, according to a press release from Lilly.
Participants with obesity and knee arthritis who took a 12-mg dose of retatrutide saw an average weight loss of 71.8 lbs (28.7%) at 68 weeks. (iStock)
Seven additional phase 3 trials for retatrutide are expected to wrap up in 2026. The drug could see FDA approval in 2027, according to GoodRx.
The Lilly spokesperson noted that there have been no studies comparing retatrutide to GLP-1 treatments due to “differences in study design and patient populations.”
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
Despite limited data availability on the drug, the medication could also be applied to treat other conditions like type 2 diabetes, kidney disease, cardiovascular risk reduction and metabolic dysfunction, according to GoodRx and other experts.
Fox News senior medical analyst Dr. Marc Siegel noted that Lilly’s Zepbound and Mounjaro already target two metabolic pathways — GLP-1 and GIP — which work together to promote weight loss, reduce hunger and inflammation, improve insulin function and slow digestion.
The doctor confirmed that the new drug, with its third receptor agonist, will further decrease hunger while increasing the feeling of fullness.
More than one in eight patients reported being “completely free” from knee pain at the end of the trial. (iStock)
“The weight loss in clinical trials is even more substantial, and the most likely reason that it decreases orthopedic problems is because of the weight loss — less stress on the joints and the decreased inflammation,” Siegel added.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
The most common side effect of GLP-3s is gastrointestinal symptoms, the doctor confirmed. Rarer side effects may include pancreatitis, gallstones and heart arrhythmia.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
Philip Rabito, M.D., a specialist in endocrinology, weight loss and wellness in New York City, shared in an interview with Fox News Digital that this new class of weight-loss drugs is positioned to “approach bariatric surgery level outcomes” — although it doesn’t come without risks.
“The novel glucagon‑agonist component introduces less‑understood long‑term safety considerations, so it is imperative that patients are followed closely by healthcare professionals experienced with this class of medicines, with cautious, stepwise use, despite the impressive efficacy,” he cautioned.
How bits of Apple history can be yours
Trevor Noah caps off ‘generational run,’ will host Grammys for sixth and final time
We zoomed down California’s longest and fastest zip lines. Here are 6 things to know
House Democrats challenge new Homeland Security order limiting lawmaker visits to immigration facilities
At 89, he’s heard six decades of L.A.’s secrets and is ready to talk about what he’s learned
Florida High School Football Rankings: Top 25 teams – Oct. 21
Cleary's 21 help Le Moyne down Central Connecticut State 69-64 in OT
How old is Bo Nix? What to know about Oregon quarterback ahead of 2024 NFL Draft
99th annual Pony Swim held in Virginia
Video: ‘It Didn’t Have to Happen This Way:’ U.Va. Faculty Call for Review of Police Response to Protests
Fact check: Machado can’t ‘share’ her Nobel Peace Prize with Trump
Scott Adams, the controversial cartoonist behind ‘Dilbert,’ dies at 68
Rep Ro Khanna demands prosecution of ICE agent in Minneapolis fatal shooting
Syrian army sends troops to rural Aleppo to stop any SDF attempt to regroup
Iran acknowledges mass protest deaths, but claims situation under control as Trump mulls response
-
Detroit, MI1 week ago2 hospitalized after shooting on Lodge Freeway in Detroit
-
Technology1 week agoPower bank feature creep is out of control
-
Montana3 days agoService door of Crans-Montana bar where 40 died in fire was locked from inside, owner says
-
Delaware4 days agoMERR responds to dead humpback whale washed up near Bethany Beach
-
Dallas, TX5 days agoAnti-ICE protest outside Dallas City Hall follows deadly shooting in Minneapolis
-
Dallas, TX1 week agoDefensive coordinator candidates who could improve Cowboys’ brutal secondary in 2026
-
Iowa7 days agoPat McAfee praises Audi Crooks, plays hype song for Iowa State star
-
Virginia3 days agoVirginia Tech gains commitment from ACC transfer QB